Health

Pharma Setbacks and FDA Safety Concerns

Updated 2026-10-09 13:25 UTC 1 source Negative

The FDA has flagged a potential safety signal after four patient deaths in a schizophrenia drug trial. Argenx faces an unusual setback, while Lilly is involved in lawsuits over copycat obesity drugs.

Coverage timeline — 1 article

STAT News

STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more

The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.

2026-10-09 13:17 UTC